by Andrii Buvailo, PhD
AI drug discovery has moved from platform pitches to clinical tests. One recent sign: in October 2026, Iambic Therapeutics raised $150 million in a Nasdaq IPO, saying in its filing …
Read More
by Andrii Buvailo, PhD
With Science Foundries, launched today, the R&D software company moves from helping scientists with individual tasks to managing entire scientific processes with teams of AI agents. The launch builds on …
Read More
by Andrii Buvailo, PhD
Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: …
Read More
by Andrii Buvailo, PhD
Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with. …
Read More
by Andrii Buvailo, PhD, Roman Kasianov
Inside the growing bet that AI can find the patients pharma's failed trials missed... Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million …
Read More
by Andrii Buvailo, PhD
Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a …
Read More